Recombinant Human Ceramide glucosyltransferase (UGCG)-VLPs

What is the role of UGCG in virus-like particle production?

UDP-glucose ceramide glucosyltransferase (UGCG) plays a significant role in the production and efficiency of virus-like particles (VLPs). This enzyme catalyzes the first glycosylation step of ceramides, leading to the production of glucosylceramide and subsequently more complex glycosphingolipids. Research demonstrates that UGCG overexpression can significantly improve transfection efficiency by removing intracellular polyplex sequestration, consequently enhancing VLP production. This becomes particularly relevant when addressing the cell density effect (CDE), where high cell densities typically result in reduced transfection efficiency and decreased VLP yields. Studies have shown that UGCG overexpression can improve transfection efficiency by approximately 45% at high cell densities (12 × 10^6 cells/mL), making it a valuable target for optimizing recombinant protein production systems .

How does the cell density effect (CDE) impact UGCG-related VLP production?

The cell density effect is a significant phenomenon in bioprocess development where transfection efficiency and subsequent protein or VLP production dramatically decreases as cell culture density increases. Experimental data reveals that when cells reach densities higher than 6 × 10^6 cells/mL, transfection efficiency sharply declines, completely preventing VLP production at higher densities . This effect occurs despite sufficient plasmid DNA delivery and adequate energy substrate availability, as glucose and lactate concentrations remained at approximately 2 g/L in the culture medium during experiments.

UGCG's relationship to this effect stems from its impact on intracellular vesicle trafficking and membrane composition. Overexpression of UGCG helps mitigate the CDE by removing intracellular polyplex sequestration, allowing DNA-polymer complexes (polyplexes) used for transfection to avoid becoming trapped in intracellular compartments. Research has demonstrated that combining UGCG overexpression with extracellular vesicle (EV) depletion resulted in approximately 45% improvement in transfection efficiency at high cell densities (12 × 10^6 cells/mL), effectively counteracting the CDE's negative impacts .

How can VLPs incorporating UGCG be accurately quantified in research settings?

Multiple methodologies exist for the accurate quantification of VLPs in research settings:

Fluorescence-based quantification

For fluorescently tagged VLPs (such as Gag::eGFP constructs), relative fluorescence unit (RFU) values can be calculated by subtracting fluorescence unit values of non-transfected negative control samples. The fluorescence intensity correlates linearly with p24 values determined using ELISA, allowing conversion to Gag::eGFP concentration using the equation:

Gag::eGFP (ng/mL) = (RFU × 5 + 3.5) × 36

The factor 36 accounts for the molecular weight difference between p24 and Gag::eGFP and corrects for underestimation when using p24 ELISA for Gag concentration estimation .

Particle number calculation

Assuming that a single VLP contains 2500 Gag::eGFP molecules and one Gag::eGFP is 84 kDa (1.39 × 10^-10 ng), the concentration of VLPs can be calculated from the Gag::eGFP concentration .

Nanoparticle Tracking Analysis (NTA)

This technique quantifies both fluorescent particles (VLPs with fluorescent tags) and total diffracting particles (including non-fluorescent EVs). By comparing fluorescent to total particles, researchers can determine the purity of their VLP preparations. Research has shown that VLPs typically represent approximately 68 ± 4% of total diffracting particles in ultracentrifugation-purified samples .

Ultracentrifugation concentration

Studies demonstrate that VLPs can be concentrated approximately 15 times (from ~1.5 × 10^10 to ~2.3 × 10^11 VLPs/mL) using ultracentrifugation, which is crucial for downstream applications requiring higher VLP concentrations .

What experimental methods are commonly used to study UGCG function in VLP research?

Several established experimental methods are employed to investigate UGCG function in relation to VLPs:

Genetic manipulation approaches

• CRISPR/Cas9 gene knockout: Generation of UGCG knockout cell lines (such as HEK 293 and A549) to study UGCG's role in viral entry and VLP production .

• Overexpression studies: Transfection with UGCG-expressing plasmids to improve transfection efficiency and mitigate the cell density effect in VLP production .

Pharmacological approaches

• UGCG inhibition: Use of PPMP (1-phenyl-2-palmitoylamino-3-morpholino-1-propanol), a pharmacological inhibitor of UGCG, as an alternative approach to study UGCG function without genetic modification .

Functional assays

• β-lactamase-based VLP entry assays: VLPs containing a β-lactamase-M1 fusion protein and bearing various viral glycoproteins are used to assess viral entry. The β-lactamase cleaves a fluorescent substrate (CCF2) in the cytoplasm, allowing quantification of entry by flow cytometry .

• Pseudovirus infection assays: VSV-based pseudoviruses encoding GFP and bearing different viral glycoproteins to assess infection efficiency through GFP expression analysis by flow cytometry .

Analytical techniques

• Extracellular vesicle depletion: Methods for removing extracellular vesicles from culture medium to improve transfection efficiency and VLP production .

• Nanoparticle tracking analysis (NTA): Quantification and characterization of both fluorescent VLPs and non-fluorescent extracellular vesicles in preparations .

• Proteomic analysis: Mass spectrometry characterization of protein composition in VLPs and copurified extracellular vesicles under different production conditions .

• High-performance thin-layer chromatography (HPTLC): Assessment of glucosylceramide and other glycosphingolipids in UGCG-manipulated cells .

How do extracellular vesicles (EVs) interact with UGCG-VLPs during production?

Extracellular vesicles play a complex role during VLP production, acting as significant inhibitors of transfection efficiency, particularly at high cell densities. Research indicates that EVs can interact with polyplexes (DNA-polymer complexes used for transfection), potentially causing macroaggregation and reducing cellular entry capability . This interaction represents a key component of the cell density effect (CDE).

The relationship between EVs and VLPs during production has been characterized using nanoparticle tracking analysis (NTA) to distinguish between fluorescent VLPs and non-fluorescent EVs. Studies have found that transfection itself does not significantly influence EV production, but when cells produce VLPs, there is a significant increase in the total number of particles. In purified samples, VLPs represented approximately 68 ± 4% of the total diffracting particles, with the remaining being copurified EVs with similar density to VLPs .

Several strategies have proven effective in mitigating EV inhibitory effects:

• EV depletion from culture medium: This approach improved VLP production by approximately 60% at low cell densities (2 × 10^6 cells/mL) and increased extracellular fluorescence by approximately 20%, indicating improved VLP budding .

• Complete medium replacement: Removing the culture medium before transfection eliminates EVs and other inhibitory factors, improving transfection efficiency .

• Combined EV depletion with UGCG overexpression: This dual approach showed the most significant improvement, increasing transfection efficiency by approximately 45% at high cell densities (12 × 10^6 cells/mL) .

Interestingly, polyplexes formed in EV-depleted medium showed resistance to EV inhibition when subsequently exposed to EVs, suggesting that medium composition might buffer EV-induced macroaggregation .

What are the contrasting findings regarding UGCG essentiality for cell proliferation?

Research on UGCG's role in cell proliferation has yielded contradictory findings that impact experimental design considerations:

Evidence for non-essentiality

Studies by Yamashita et al. showed no discernible difference in proliferation rates between UGCG-deleted embryonic stem cells and wildtype cells in vitro, despite the complete absence of glycosphingolipid synthesis in the knockout cells .

Evidence for essentiality

In contrast, nude mice studies demonstrated that silencing the UGCG gene in adriamycin-resistant MCF-7 cells (which overexpress UGCG) inhibited tumor xenograft growth in vivo. This aligns with findings from the Sabatini Lab showing that UGCG is essential for optimal proliferation of several cancer cell lines .

Cell-type specificity

The Sabatini Lab developed a CRISPR-based approach to assess gene essentiality and found varying essentiality scores for UGCG across different cell lines, suggesting that UGCG's importance for cell proliferation is cell-type specific .

Mechanistic considerations

These findings necessitate careful consideration of cell line selection for UGCG-VLP studies, as manipulation impacts may vary significantly between different cell types. The discrepancy between in vitro and in vivo results suggests that environmental factors present in living organisms might influence UGCG function, potentially affecting the interpretation of UGCG-VLP production studies conducted solely in cell culture.

How do different viral glycoproteins interact with UGCG, and what are the implications for VLP design?

Viral glycoproteins demonstrate varying dependencies on UGCG for efficient cell entry, with important implications for VLP design:

Influenza virus glycoproteins

Knockout of UGCG reduced entry of VLPs bearing influenza virus hemagglutinin (HA) and neuraminidase (NA) glycoproteins in both HEK 293 and A549 cell lines. This indicates a significant role for UGCG and, by extension, glucosylceramide and/or downstream glycosphingolipids in influenza virus entry .

Vesicular Stomatitis Virus (VSV) glycoprotein

The dependency on UGCG was cell-type specific. VLPs bearing VSV glycoprotein (G) showed reduced entry in HEK 293 UGCG KO cells but were unaffected in A549 KO cells. This suggests the existence of alternative pathways or compensatory mechanisms in A549 cells that are absent in HEK 293 cells .

Ebola virus (EBOV) glycoprotein

VLPs bearing EBOV glycoprotein showed the most pronounced reduction in entry in both UGCG KO cell lines, and to a greater extent than observed with influenza or VSV glycoproteins. This indicates a stronger dependency on UGCG-dependent pathways for EBOV entry .

Measles virus glycoproteins

In contrast to other viruses, infection by VSV pseudoviruses bearing measles virus H and F proteins was unaffected in HEK 293 UGCG KO cells and actually increased in A549 UGCG KO cells. This suggests that UGCG might negatively regulate measles virus entry in certain cell types .

These findings have significant implications for VLP design:

• Glycoprotein selection: When designing VLPs for specific applications (such as vaccine development or drug delivery), researchers should consider the dependency of different viral glycoproteins on UGCG, especially if targeting specific cell types or tissues.

• Cell type targeting: The cell-type specificity of UGCG dependence for VSV and measles virus suggests that manipulating UGCG expression could potentially be used to enhance or restrict VLP entry into specific cell types.

• Entry efficiency optimization: For VLPs designed to efficiently enter cells, incorporating glycoproteins with appropriate UGCG dependency for the target cell type could significantly improve performance.

• Fusion mechanism considerations: Since all tested viruses enter cells through endosomal pathways but show different UGCG dependencies, researchers should consider how membrane composition (influenced by UGCG) affects fusion at different endosomal pH levels when designing VLPs .

What proteomic changes occur in the extracellular environment during UGCG-influenced VLP production?

Mass spectrometry analyses have revealed significant proteomic alterations in the extracellular environment during VLP production, with several implications for UGCG-related research:

Upregulated pathways in VLP production

• RNA processing and protein translation pathways: These showed increased activity, correlating with the enhanced metabolic state of cells engaged in protein production .

• Immune activation proteins: Proteins related to antigen processing and presentation increased during VLP production, suggesting membrane proteins in VLPs and copurified EVs might function as adjuvants in immunization strategies .

Downregulated pathways in VLP production

• Microtubule-based processes: Including localization of Cajal bodies, protein folding, and certain viral process GO terms .

• Nuclear transport proteins: Including NUP155, NUP160, and importins like IPO7, while proteins involved in protein translation within this GO term were upregulated .

• Vesicle transport components: Proteins involved in microtubule-based vesicle transport (CCTs, heat shock proteins, PPIA, calnexin, COPB2) were downregulated, indicating a shift in microvesicle transport during VLP production .

Stress responses

• Oxidative stress markers: Oxidative stress-related proteins increased in the EV environment during VLP production, reflecting disruption of cellular homeostasis when VLP production is engaged .

These proteomic changes have several important implications for experimental design in UGCG-VLP research:

• Oxidative stress considerations: Researchers should account for potential oxidative stress impacts when designing long-term VLP production protocols, particularly when manipulating UGCG levels.

• Vesicle trafficking competition: The altered expression of proteins involved in vesicle transport suggests that VLP budding mechanisms may compete with natural EV production pathways, which could be influenced by UGCG activity.

• Immunological implications: The presence of immune-activating proteins in VLP-EV mixtures could affect immunological studies using these particles, potentially providing adjuvant effects.

• Purification considerations: When purifying VLPs, researchers should recognize that copurified EVs may contain different protein compositions depending on whether they were produced under transfection conditions with varying UGCG expression levels .

What regulatory mechanisms control UGCG expression, and how might these be leveraged for enhanced VLP production?

Several key regulatory mechanisms controlling UGCG expression have been identified:

Transcription factor Sp1

Studies have demonstrated that doxorubicin treatment increases UGCG mRNA and protein levels in ER-positive MCF-7 cells, but only slightly in ER-negative MDA-MB-231 cells. This increase is associated with doxorubicin resistance. Inhibition of transcription factor Sp1, which has a binding site at the UGCG promoter, prevents doxorubicin-induced upregulation of UGCG, reverses doxorubicin resistance, and promotes apoptosis .

Estrogen Receptor alpha (ERα)

Blocking ERα also prevents UGCG upregulation after doxorubicin treatment in ER-positive cells. ERα promotes cell proliferation through direct transcriptional upregulation of several proliferation-promoting genes, including UGCG .

These regulatory mechanisms could potentially be leveraged to enhance VLP production in several ways:

• Targeted upregulation of UGCG: Activating Sp1-mediated transcription of UGCG in a controlled manner could increase UGCG expression, potentially improving transfection efficiency and VLP production. This could be achieved through chemical modulators of Sp1 activity or through genetic approaches to enhance Sp1 binding to the UGCG promoter.

• ERα modulation in ER-positive cells: In cell lines expressing ERα, selective modulation of this receptor could be used to upregulate UGCG expression, though this approach would be limited to ER-positive cells.

• Promoter engineering: Understanding the regulatory elements in the UGCG promoter, such as the Sp1 binding site, opens possibilities for engineering expression vectors with enhanced or inducible UGCG expression specifically designed for improved VLP production.

• Cell line selection: The differential regulation of UGCG in different cell types suggests that selecting cell lines with naturally high UGCG expression or with regulatory machinery conducive to UGCG upregulation might be advantageous for VLP production systems .

How might UGCG manipulation be used to optimize viral entry for vaccine development using VLPs?

The influence of UGCG on viral entry mechanisms presents significant opportunities for vaccine development using VLPs:

Entry enhancement for antigen presentation

Since UGCG influences the entry of VLPs bearing glycoproteins from multiple viruses, including influenza, VSV, and EBOV, targeted upregulation of UGCG in antigen-presenting cells could potentially enhance VLP uptake and subsequent immune response stimulation . This could be particularly beneficial for vaccines against viruses showing strong UGCG dependency, such as Ebola virus.

Cell-specific targeting

The differential effects of UGCG knockout on viral glycoprotein-mediated entry in different cell lines suggest that UGCG manipulation could be used to direct VLPs to specific cell types. For example, VLPs bearing measles virus glycoproteins showed increased entry in A549 UGCG KO cells, indicating potential for cell-specific targeting strategies .

Improved VLP production systems

Combining UGCG overexpression with extracellular vesicle depletion significantly improved transfection efficiency (by ~45%) at high cell densities, which could translate to more efficient and cost-effective VLP production for vaccine manufacturing .

Adjuvant development

Proteomic analysis revealed that VLP production increases proteins related to immune activation (antigen processing and presentation) in the extracellular environment. This suggests that manipulating UGCG to enhance certain EV populations could potentially improve the adjuvant properties of VLP-based vaccines .

Modulation of antigen uptake mechanisms

The relationship between UGCG and endosomal entry pathways suggests that UGCG manipulation could potentially influence how VLP-delivered antigens are processed within antigen-presenting cells, potentially affecting the balance between MHC class I and class II presentation and subsequent T cell responses .

These strategies require careful optimization as the effects of UGCG manipulation are both virus- and cell-type specific, necessitating tailored approaches depending on the target pathogen and intended vaccine application.